0001416377-17-000004.txt : 20170405 0001416377-17-000004.hdr.sgml : 20170405 20170405141815 ACCESSION NUMBER: 0001416377-17-000004 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170405 DATE AS OF CHANGE: 20170405 EFFECTIVENESS DATE: 20170405 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viracta Therapeutics, INC. CENTRAL INDEX KEY: 0001416377 IRS NUMBER: 260814473 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-284113 FILM NUMBER: 17742134 BUSINESS ADDRESS: STREET 1: 4747 EXECUTIVE DRIVE STREET 2: SUITE 700 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584008470 MAIL ADDRESS: STREET 1: 4747 EXECUTIVE DRIVE STREET 2: SUITE 700 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: HEMAQUEST PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20120321 FORMER COMPANY: FORMER CONFORMED NAME: HEMAQUEST PHARMACEUTICALS DATE OF NAME CHANGE: 20090108 FORMER COMPANY: FORMER CONFORMED NAME: HemaGenex Pharmaceuticals Inc DATE OF NAME CHANGE: 20071026 D 1 primary_doc.xml X0707 D LIVE 0001416377 Viracta Therapeutics, INC. 4747 EXECUTIVE DRIVE SUITE 700 SAN DIEGO CA CALIFORNIA 92121 8584008470 DELAWARE HEMAQUEST PHARMACEUTICALS, INC. HEMAQUEST PHARMACEUTICALS HemaGenex Pharmaceuticals Inc Corporation true David Slack c/o Viracta Therapeutics, Inc. 4747 Executive Drive, Suite 700 San Diego CA CALIFORNIA 92121 Executive Officer Ivor Royston c/o Viracta Therapeutics, Inc. 4747 Executive Drive, Suite 700 San Diego CA CALIFORNIA 92121 Executive Officer Director Richard Ghalie c/o Viracta Therapeutics, Inc. 4747 Executive Drive, Suite 700 San Diego CA CALIFORNIA 92121 Director James Woody c/o Viracta Therapeutics, Inc. 4747 Executive Drive, Suite 700 San Diego CA CALIFORNIA 92121 Director Patrick Soon-Shiong c/o Viracta Therapeutics, Inc. 4747 Executive Drive, Suite 700 San Diego CA CALIFORNIA 92121 Director Biotechnology Decline to Disclose 06b false 2017-03-23 false true false 0 26875622 9875623 16999999 $8,799,999.02 in new money; $1,075,624.54 in conversion of promissory notes. false 9 0 0 0 false Viracta Therapeutics, INC. /s/ David Slack David Slack Chief Business Officer 2017-03-30